Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer? Graham Pawelec Article Pages: 343 - 345
Signaling defects in T lymphocytes of patients with malignancy Theresa L. Whiteside REVIEW Pages: 346 - 352
Function and dysfunction of CD4+ T cells in the immune response to melanoma Wolfgang H. FischerPer thor StratenJürgen C. Becker REVIEW Pages: 363 - 370
Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms Craig L. Slingluff REVIEW Pages: 371 - 373
Selective MHC expression in tumours modulates adaptive and innate antitumour responses Robert C. ReesShahid Mian REVIEW Pages: 374 - 381
Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer Hiroaki YanagawaEiji TakeuchiSaburo Sone ORIGINAL ARTICLE Pages: 396 - 400
HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells Larry D. Anderson Jr.J. Michael HudsonConstantin G. Ioannides ORIGINAL ARTICLE Pages: 401 - 410
Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies Tove OlafsenCharlotte K. Munthe LundTerje E. Michaelsen ORIGINAL ARTICLE Pages: 411 - 418
Effective cancer therapy with a single injection of interleukin-2 at the site of the tumour Willem Den OtterJenny CadéeRachel Stewart SHORT COMMUNICATION Pages: 419 - 420